DrugBiological
Ixekizumab clinical trials
Also written LY2439821 and Taltz.
- studies test it
- 54
- open now
- 10
- in phase 3
- 23
- first study started
- 2009
Keep track of what changes. Save the ixekizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2017 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 5 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 5 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 10
- Phase 3
- 23
- Phase 4
- 9
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 36 · Other 18
Eli Lilly and Company (34) · Second Affiliated Hospital, School of Medicine, Zhejiang University (3) · Göteborg University (1) · Celltrion (1) · Yale University (1) · Radboud University Medical Center (1) · Icahn School of Medicine at Mount Sinai (1) · Jeffrey Curtis (1)
Often tested with
Tested in the same studies.
Secukinumab (7) · Guselkumab (6) · Tofacitinib (4) · Etanercept (4) · Adalimumab (4) · Methotrexate (4) · Risankizumab (3) · Bimekizumab (3)
Studies
Open first, then newest update. How each study uses ixekizumab is read from its arms, and is right about nine times in ten.
Testing it · 54
- A Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of SB35 (Proposed Ixekizumab Biosimilar) to Taltz in Healthy ParticipantsRecruitingPhase 1Samsung Bioepis Co., Ltd.NCT07789964Written as Ixekizumab
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Ixekizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Ixekizumab
- Combination of Biologic and Anti-obesity Therapies in Psoriatic ArthritisRecruitingNot applicableNHS Greater Glasgow and ClydeNCT07443956Written as Ixekizumab
- Proactive TDM Versus Standard Use of Biologics in PsoriasisRecruitingPhase 4University Hospital, GhentNCT06398106Written as Proactive TDM-based dosing of ixekizumab
- Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate PsoriasisNot yet recruitingPhase 2/3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06374979Written as Ixekizumab
- Ixekizumab Versus Secukizumab in Over 70-year-old Patients with PsoriasisNot yet recruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06811558Written as Ixekizumab
- Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05503875Written as adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate
- Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque PsoriasisRecruitingPhase 4Singapore General HospitalNCT04537689Written as Ixekizumab
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Ixekizumab
- A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisActive, not recruitingPhase 3Eli Lilly and CompanyNCT04527380Written as Ixekizumab
- Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic StenosisCompletedPhase 2Yale UniversityNCT05309616Written as Taltz
- Ixekizumab Diabetes Intervention Trial (I-DIT)Active, not recruitingPhase 2Göteborg UniversityNCT04589325Written as Ixekizumab
- Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedPhase 4Radboud University Medical CenterNCT04340076Written as Ixekizumab
- Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy SubjectsActive, not recruitingPhase 1CelltrionNCT07200986Written as Ixekizumab
- A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in IndiaCompletedPhase 4Eli Lilly and CompanyNCT05855967Written as Ixekizumab
- Targeting IL-17A for Treatment-Resistant DepressionCompletedPhase 2Icahn School of Medicine at Mount SinaiNCT04979910Written as Ixekizumab
- COVID-19 VaccinE Response in Rheumatology PatientsCompletedPhase 4Jeffrey CurtisNCT05080218Written as Ixekizumab
- An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma GangrenosumCompletedPhase 2Ohio State UniversityNCT03137160Written as Ixekizumab
- A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial SpondyloarthritisCompletedPhase 3Eli Lilly and CompanyNCT04285229Written as Ixekizumab
See all 54 studies that test ixekizumab →
Given in every arm · 4 — ixekizumab is usual care beside what is tested
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06588283Written as Ixekizumab
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or OverweightCompletedPhase 3Eli Lilly and CompanyNCT06588296Written as Ixekizumab
- A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial SpondyloarthritisCompletedPhase 3Eli Lilly and CompanyNCT02696785Written as Ixekizumab
- A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic TreatmentCompletedPhase 3Eli Lilly and CompanyNCT02634801Written as Ixekizumab
As the comparator · 1 — what is tested is compared with ixekizumab
Codes
What other systems call ixekizumab · ClinicalTrials.gg INT005612
- MeSH (NLM) C549079ixekizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) BTY153760OIXEKIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1745099Confirmed FDA, Wikidata
- Wikidata Q13574436ixekizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C174646IxekizumabOne source FDA
- DrugBank DB11569One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C549079 | ixekizumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | BTY153760O | IXEKIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1745099 | — | Confirmed FDA, Wikidata |
| Wikidata | Q13574436 | ixekizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C174646 | Ixekizumab | One source FDA |
| DrugBank | DB11569 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.